Follow Us      


   Offical Journal of The Academy of Osseointegration

Share Page:

Volume 22 , Issue 3
May/June 2002

Pages 259–267

Clinical Evaluation of an Enamel Matrix Protein Derivative (Emdogain) Combined with a Bovine-Derived Xenograft (Bio-Oss) for the Treatment of Intrabony Periodontal Defects in Humans

Anton Sculean, DMD, Dr Med Dent, MS, PhD, Giovanni Carlo Chiantella DDS, MS**/Péter Windisch, DMD, István Gera, DMD, PhD, Elmar Reich, DDS, Dr Med Dent, PhD

PMID: 12186348
DOI: 10.11607/prd.00.0471

The purpose of the present study was to compare the treatment of deep intrabony defects with a combination of an enamel matrix protein derivative (EMD; Emdogain) and a bovine-derived xenograft (BDX; Bio-Oss) to BDX alone. Twenty-four healthy patients, each of whom displayed one intrabony defect, were randomly treated with a combination of EMD + BDX (test) or with BDX alone (control). Soft tissue measurements were made at baseline and 1 year following the therapy. No differences in any of the investigated parameters were observed at baseline between the two groups. No adverse healing response was observed in any of the patients. At 1 year after therapy, the sites treated with EMD + BDX showed a reduction in probing pocket depth (PPD) from 10.0 ± 1.5 mm to 4.3 ± 1.4 mm and a change in clinical attachment level (CAL) from 10.9 ± 2.0 mm to 6.2 ± 1.9 mm (P < .0001). In the group treated with BDX, the PPD was reduced from 9.7 ± 2.4 mm to 3.2 ± 0.7 mm and the CAL changed from 10.1 ± 2.3 mm to 5.2 ± 1.2 mm (P < .0001). Hard tissue fill was observed radiographically in all defects. Both treatments resulted in significant improvements of PPD and CAL. However, no statistically significant differences in any of the investigated parameters were observed between the test and control groups. Both therapies led to significant improvements of the investigated clinical parameters. (Int J Periodontics Restorative Dent 2002;22:259–267.)

Full Text PDF File | Order Article


Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.


© 2020 Quintessence Publishing Co, Inc

PRD Home
Current Issue
Ahead of Print
Author Guidelines
Submission Form
Quintessence Home
Terms of Use
Privacy Policy
About Us
Contact Us